Genmab A/S (GNMSF) Enterprise Value (2018 - 2026)
Genmab A's (GNMSF) quarterly Enterprise Value came in at -$1.5 billion in Q1 2026, up 10.48% YoY from -$1.4 billion in Q1 2025, and up 11.31% on a QoQ basis from -$1.7 billion in Q4 2025.
Genmab A/S (GNMSF) Enterprise Value (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 7 years of Enterprise Value data on file, last reported at -$1.5 billion in Q1 2026.
- Quarterly Enterprise Value rose 10.48% year-over-year to -$1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 billion (up 10.48% YoY) and the FY2025 annual result came in at -$1.7 billion, up 41.94% from the prior year.
- Enterprise Value rose to -$1.5 billion in Q1 2026, from -$1.7 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$43.0 million in Q3 2024 to a low of -$2.9 billion in Q2 2025.
- A 4-year average of -$1.4 billion and a median of -$1.6 billion in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 42.14% — and 2025, when it slumped 4320.93%.
- Tracing GNMSF's Enterprise Value over 4 years: stood at -$2.4 billion in 2023, then surged by 42.14% to -$1.4 billion in 2024, then decreased by 23.29% to -$1.7 billion in 2025, then gained by 11.31% to -$1.5 billion in 2026.
- The last three Enterprise Value figures came in at -$1.5 billion (Q1 2026), -$1.7 billion (Q4 2025), and -$1.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.50 Bn |
| Mar 31, 2026 | -1.52 Bn |
| Dec 31, 2025 | -1.72 Bn |
| Sep 30, 2025 | -1.90 Bn |
| Jun 30, 2025 | -2.90 Bn |
| Mar 31, 2025 | -1.70 Bn |
| Dec 31, 2024 | -1.39 Bn |
| Sep 30, 2024 | -43.00 Mn |
| Jun 30, 2024 | -624.00 Mn |
| Mar 31, 2024 | -130.00 Mn |
| Dec 31, 2023 | -2.40 Bn |
| Sep 30, 2020 | -8,892,000.00 Bn |
| Dec 31, 2019 | -4,643.00 |
| Sep 30, 2019 | -4.64 Bn |
| Dec 31, 2018 | -896.07 Mn |